We are live on ! Find out more
TRAW icon

Traws Pharma
TRAW

11 hedge funds and large institutions have $1.15M invested in Traws Pharma in 2016 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

15% less capital invested

Capital invested by funds: $1.36M → $1.15M (-$207K)

15% less funds holding

Funds holding: 13 → 11 (-2)

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $2K

Holders
11
Holders Change
-2
Holders Change %
-15.38%
% of All Funds
0.29%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
1
Reduced
1
Closed
4
Calls
–
Puts
$2K
Net Calls
-$2K
Net Calls Change
-$2K

Top Buyers

Rank Fund Capital Flow
1
AFM
Anson Funds Management
Texas
+$349K
2
Renaissance Technologies
Renaissance Technologies
New York
+$63.4K
3
Deutsche Bank
Deutsche Bank
Germany
+$31.7K

Top Sellers

Rank Fund Capital Flow
1
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$65K
2
Citigroup
Citigroup
New York
-$31.7K
3
UBS Group
UBS Group
Switzerland
-$31.7K
4
VKH
Virtu KCG Holdings
New York
-$31.7K
5
ARTA
A.R.T. Advisors
New York
-$28K
Name Holding Trade Value Shares
Change 		Change in
Stake
AFM
1
Anson Funds Management
Texas
$367K +$349K +11 New
Vanguard Group
2
Vanguard Group
Pennsylvania
$184K – – –
Renaissance Technologies
3
Renaissance Technologies
New York
$163K +$63.4K +2 +67%
WMSA
4
Weiss Multi-Strategy Advisers
New York
$154K – – –
Citigroup
5
Citigroup
New York
$73K -$31.7K -1 -33%
DLA
6
Douglas Lane & Associates
New York
$41K +$31.7K +1 New
BFA
7
BlackRock Fund Advisors
California
$20K – – –
Deutsche Bank
8
Deutsche Bank
Germany
$20K +$31.7K +1 New
Citadel Advisors
9
Citadel Advisors
Florida
$19K – – –
Royal Bank of Canada
10
Royal Bank of Canada
Ontario, Canada
$17K – – –
HK
11
Horizon Kinetics
New York
$14K – – –
UBS Group
12
UBS Group
Switzerland
$13K -$31.7K -1 Closed
Goldman Sachs
13
Goldman Sachs
New York
$13K – – –
HighTower Advisors
14
HighTower Advisors
Illinois
$11K – – –
Northern Trust
15
Northern Trust
Illinois
$11K – – –
VKH
16
Virtu KCG Holdings
New York
$8K -$31.7K -1 Closed
Creative Planning
17
Creative Planning
Kansas
$8K – – –
HSBC Holdings
18
HSBC Holdings
United Kingdom
$8K – – –
BCM
19
Bridgeway Capital Management
Texas
$7K – – –
BIM
20
BlackRock Investment Management
Delaware
$1K – – –
Geode Capital Management
21
Geode Capital Management
Massachusetts
$26 – – –
ARTA
22
A.R.T. Advisors
New York
– -$28K -1 Closed
Jacobs Levy Equity Management
23
Jacobs Levy Equity Management
New Jersey
– -$65K -1 Closed
TRCT
24
Tower Research Capital (TRC)
New York
– -$1K – –

TRAW Hedge Fund Activity: Q1 2016 in Review

11 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Traws Pharma (TRAW) for Q1 2016, worth a combined $1.15M — down 15% from $1.36M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of TRAW and 3 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 1 added.

The largest buyer was Anson Funds Management, opening a new position worth an estimated $349K. The largest seller was Jacobs Levy Equity Management, exiting entirely with an estimated $65K sold.

  • 11 institutional investors held Traws Pharma (TRAW) as of Q1 2016, down from 13 in Q4 2015.
  • Funds reported $1.15M of Traws Pharma stock for Q1 2016, down 15% quarter-over-quarter.
  • 3 funds opened new Traws Pharma positions in Q1 2016 and 4 closed out, a net change of -1 holder.
  • The largest Traws Pharma buyer in Q1 2016 was Anson Funds Management, an estimated $349K added.
  • The largest Traws Pharma seller in Q1 2016 was Jacobs Levy Equity Management, an estimated $65K sold.

Based on aggregated 13F filings for Q1 2016.